| 영문 | purpura | 한글 | 자색반증 |
|---|---|---|---|
| 설명 | 피부내의 출혈로 인하여, 피부 표피를 통하여 쉽게 보이는 자홍색 혹은 적갈색 반점을 특징으로 하는 일련의 질환을 총칭하는 용어이다. 대개 홍반과 구별해야 하는 데 홍반은 피부밑의 혈관이 팽창하여 붉게 보이는 현상으로 투명한 자를 이용하여 피부를 눌러서 관찰해보면 쉽게 구별이 가능하다. 이때 홍반은 붉은 색이 없어지지만, 자반은 붉은 색이 없어지지 않는다. |
||
| ITP | idiopathic thrombocytopenic purpura; immune thrombocytopenia; immunogenic thrombocytopenic purpura; ... |
|---|---|
| ATP | 1) Adenosine Tri-Phosphate 2) Autoimmune Thrombocytopenic Purpura |
| ITP | Idiopathic(Immune) Thrombocytopenic Purpura |
| TTP | Thrombotic Thrombocytopenic Purpura |
| AITP | autoimmune idiopathic thrombocytopenic purpura |
| AITP | Autoimmune thrombocytopenic purpura |
|---|---|
| ATP | Autoimmune thrombocytopenic purpura |
| ITP | Idiopathic thrombocytopenic purpura |
| ITP | Immune thrombocytopenic purpura |
| TTP | Thrombotic Thrombocytopenic Purpura |
| purpura, thrombocytopenic | Any form of purpura in which the platelet count is decreased. Many forms are thought to be caused by immunological mechanisms. (12 Dec 1998) |
|---|---|
| purpura, thrombocytopenic, idiopathic | Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IgG autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms. (12 Dec 1998) |
| purpura, thrombotic thrombocytopenic | A disease characterised by thrombocytopenia, haemolytic anaemia, bizarre neurological manifestations, azotemia, fever, and thromboses in terminal arterioles and capillaries. (12 Dec 1998) |
| idiopathic thrombocytopenic purpura | <haematology> A rare autoimmune disorder characterised by an acute shortage of platelets with resultant bruising and spontaneous bleeding. The platelet count becomes exceedingly low and spontaneous bleeding from the gums, gastrointestinal tract and nose can be seen. Physical examination may demonstrate enlargement of the spleen. A typical rash occurs to do microscopic haemorrhage of small blood vessels in the skin. Platelet counts under 10,000 can lead to spontaneous haemorrhage into the brain causing death. Treatment with corticosteroids is generally effective. Surgical removal of the spleen (splenectomy) is reserved for some patients. Anti-platelet antibodies are detectable in some cases. It may present in either an acute or a chronic form. Acronym: ITP (20 Sep 2002) |
| immune thrombocytopenic purpura | <haematology> A low number of platelets in the blood, which is common in people with HIV, but often resolves as immune deficiency worsens. HIV-related ITP usually does not have serious consequences. Its cause has not been definitely determined. Treatment with AZT frequently alleviates the condition. (09 Oct 1997) |
| thrombocytopenic purpura | See: idiopathic thrombocytopenic purpura. (05 Mar 2000) |
| thrombotic thrombocytopenic purpura | A rapidly fatal or occasionally protracted disease with varied symptoms in addition to purpura, including signs of central nervous system involvement, due to formation of fibrin or platelet thrombi in arterioles and capillaries in many organs. Synonym: Moschcowitz' disease. (05 Mar 2000) |
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| suppressor factors, immunologic | Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|